Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Feb 9, 2012
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference

Feb 8, 2012
Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
5.67
Change:
+ 0.21
Day High:
5.89
Day Low:
5.32
Volume:
1,013,000
4:00 PM ET on Feb 22, 2012

Shareholder Tools